BCAB
BioAtla, Inc.
1.79
USD
This page is just a preview of the data found in TrendSpider’s full version
BioAtla, Inc. stock is down -3.24% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 December’s closed higher than November. 100% of analysts rate it a buy.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate.
